SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 52.40-1.5%Dec 31 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: quidditch7/21/2019 5:47:13 PM
  Read Replies (3) of 52153
 
AMRN, an observation or two, and a question:

Controversial week with timing of secondary. I was less concerned with the
offering as such than with the handling of it: pricing should have been over
night Wed into Th morning after the announcement 4:01 PM on 7/17.

The additional day for the market to stew and sell played right into the hands
of the Syndicate, dropping the price by a buck or more, easier to fill their
books. And obviously there were leaks all over the Street as price action
M - W was dreadful against a not-as-bad bt market. The price of doing
business with squid ink, I mean ilk, I guess.

Question: Shkreli and others have raised the not new issue re IP, and
whether eicosapentaenoic acid (EPA) or the process to synthesize/produce
same gives rise to patentable moat.

I'm aware of the Yee comments on EPA tail once off patent, is this a
correct analysis, assuming as it does patentability?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News